SciClone Zadaxin
Executive Summary
Thymosin alpha 1 receives approval in Italy as an influenza vaccine adjuvant, SciClone announces April 21. The firm's planned lead indication for Zadaxin in the U.S. and Europe will be as an interferon adjuvant for hepatitis C. SciClone is seeking to forge a marketing collaboration with one of the major interferon pharmaceutical manufacturers before launching a large U.S. and European Phase III trial in hepatitis C patients. Zadaxin is in Phase III for hepatitis B in Japan and is already marketed for that indication in several Asian countries. Originally a Roche compound, Zadaxin was licensed to Alpha 1 Biomedicals in the 1980s, which then sublicensed the product to SciClone for all markets excluding Italy, Spain and Portugal. SciClone acquired the sublicense for these three countries from the Italian firm Sclavo in 1997...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth